by The global immune checkpoint inhibitors market size accounted for US$ 31.4 Bn in 2021 and is projected to reach around USD 148.1 Bn by 2030, growing at a CAGR of 18.81% from 2022 to 2030.
Immune Checkpoint Inhibitors Market Key Takeaways:
- North America was accounted 47% revenue share in 2021.
- By type, the PD-L1 inhibitor segment has accounted 64% revenue hare in 2021 and is expected to grow at a CAGR of 16.8% from 2022 to 2030.
- By application, the lung cancer segment has held 37.5% revenue share in 2021.
- By region, Asia-Pacific region is expected to reach a CAGR of 18.4% from 2022 to 2030.
Report Summary
The global immune checkpoint inhibitors market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the immune checkpoint inhibitors market across the globe.
A comprehensive estimate on the immune checkpoint inhibitors market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of immune checkpoint inhibitors during the forecast period. Price point comparison by region with global average price is also considered in the study.
Immune Checkpoint Inhibitors Market Scope
| Report Coverage | Details |
| Market Size in 2022 | USD 37.31 Billion |
| Market Size by 2030 | USD 148.1 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 18.81% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Type, Disease Indication, End-Users, and Geography |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized immune checkpoint inhibitors market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Image Guided Surgery Devices Market Size Analysis 2022 To 2030
Immune Checkpoint Inhibitors Market Players
The report includes the profiles of key immune checkpoint inhibitors market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area are AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.), GlaxoSmithKline PLC, Roche Holding AG, Incyte Corporation, Novartis AG, F. Hoffmann-La Roche Ltd. (Genentech Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono Inc.), BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd.
Market Segmentation
By Drug Type
- CTLA-4 Inhibitor
- PD-1 Inhibitor
- PD-L1 Inhibitor
By Disease Indication
- Lung Cancer
- Bladder Cancer
- Melanoma
- Hodgkin lymphoma
- Others
By End-Users
- Hospitals
- Specialty Clinics
- Academic & Research Institutions
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Immune Checkpoint Inhibitors Market
5.1. COVID-19 Landscape: Immune Checkpoint Inhibitors Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Immune Checkpoint Inhibitors Market, By Drug Type
8.1. Immune Checkpoint Inhibitors Market, by Drug Type, 2022-2030
8.1.1 CTLA-4 Inhibitor
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. PD-1 Inhibitor
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. PD-L1 Inhibitor
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Immune Checkpoint Inhibitors Market, By Disease Indication
9.1. Immune Checkpoint Inhibitors Market, by Disease Indication, 2022-2030
9.1.1. Lung Cancer
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Bladder Cancer
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Melanoma
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Hodgkin lymphoma
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Immune Checkpoint Inhibitors Market, By End-Users
10.1. Immune Checkpoint Inhibitors Market, by End-Users, 2022-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Academic & Research Institutions
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Immune Checkpoint Inhibitors Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.1.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-Users (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-Users (2017-2030)
Chapter 12. Company Profiles
12.1. AstraZeneca PLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company (ARMO Biosciences.)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline PLC
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Roche Holding AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Incyte Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. F. Hoffmann-La Roche Ltd. (Genentech Inc.,)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi, Merck & Co., Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck KGaA (EMD Serono Inc.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2281
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
